USA Clears Fareston For Breast Cancer
Schering-Plough has been granted marketing approval in the USA forFareston (toremifene citrate), a once-daily antiestrogen for the first-line treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or estrogen receptor-unknown tumors.
Fareston, developed by Finland's Orion, was approved by the European Medicines Evaluation Agency last February (Marketletter February 19, 1996). The drug is targeting the same market sector as Zeneca's leading drug Nolvadex (tamoxifen), and has been described as similar or equivalent to the market leader by a Food and Drug Administration panel and the EMEA's Committee on Proprietary Medicinal Products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze